News

Expression Pathology raises $6.5 Million to develop personalized medicine assays for protein biomarkers in FFPE Tissue. April 20, 2009 (press release)

Expression Pathology Inc. announced today the move of its headquarters and R&D to a new location. March 27, 2009.

Global quantitative proteomic analyses of archival metastatic and primary melanomas discovers biomarkers potentially associated associated with melanoma progression and metastasis. PLoS ONE 4(2): e4430. doi:10.1371/journal.pone.0004430 Feb. 17, 2009

Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology, Jan. 6, 2009. Expression Pathology Inc. (EPI) announced today that the U.S. Patent and Trademark Office has issued patent number 7,473,532, which covers methods for preparing tissue for protein analysis, including EPI’s proprietary Liquid Tissue® sample preparation methodology. The claims of the patent are directed to methods that enable discovery and measurement of protein biomarkers in formalin-fixed paraffin-embedded (FFPE) tissue. (press release)

Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research, September 26, 2008. Tissue Proteomics Technology to Identify Protein Biomarkers of Metastasis (press release)

NextGen Sciences and Expression Pathology to provide protein biomarker discovery and measurement in tissue, June 30, 2008. (press release)

The Open Proteomics Journal 1, 40-45, June 15, 2008. Quantitative Proteomic Analysis of Formalin Fixed Paraffin Embedded Oral HPV Lesions from HIV Patients, Mohit Raja Jain et al (abstract)

Two of Expression Pathology's key patents covering its DIRECTOR® Slide technology for improved tissue laser microdissection have issued, May 19, 2008: Expression Pathology Inc. (EPI), a leader in tissue protein analysis, announced that two key patents have issued covering its DIRECTOR™ Slide technology for improved tissue laser microdissection. (press release)

Expression Pathology Obtains SBIR to Identify Protein Biomarkers of Breast Cancer Metastasis, May 15, 2008: Expression Pathology Inc. has been awarded a $148,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to employ its proprietary tissue microproteomics technologies to identify protein biomarkers of metastasis in primary breast cancer. (press release)

Clinical Cancer Research 14, p. 1002-1014, February 15, 2008. Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression, Vyomesh Patel et al. (abstract)

Expression Pathology Aids Research in Identifying Biomarkers of Lung Cancer Metastasis and Survival, Feb. 19, 2008: Researchers at Tokyo Medical University, using Expression Pathology’s tissue microproteomics technologies, identified protein biomarkers associated with lung cancer metastasis, which were further studied for correlation to clinical outcomes. (more)

Expression Pathology Obtains Maryland Funding to Develop Breast Cancer Test, Feb. 6, 2008: Expression Pathology Inc. (EPI), a leader in tissue protein analysis, has obtained $125,000 from the State of Maryland to develop a quantitative test for HER2 protein, an important biomarker in breast cancer tissue samples. The funding is part of the Maryland Technology Development Corporation’s Maryland Technology Transfer Fund (TEDCO MTTF) and the Maryland Venture Fund’s Challenge Investment Program. (press release)